Bio-Rad Laboratories (FRA:BUWA) Other Current Liabilities: €133 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
71 GF Score
Price €266.00
GF Value €277.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Other Current Liabilities?

Bio-Rad Laboratories FRA:BUWA +1.45% 71 Other Current Liabilities is €133 Mil as of Mar. 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 71/100 and a GF Value™ of €277.82 (Fairly Valued). The stock has 5 warning signs investors should review.

Bio-Rad Laboratories's other current liabilities for the quarter that ended in Mar. 2026 was €133 Mil.

Bio-Rad Laboratories's quarterly other current liabilities increased from Sep. 2025 (€109 Mil) to Dec. 2025 (€121 Mil) and increased from Dec. 2025 (€121 Mil) to Mar. 2026 (€133 Mil).

Bio-Rad Laboratories's annual other current liabilities declined from Dec. 2023 (€148 Mil) to Dec. 2024 (€141 Mil) and declined from Dec. 2024 (€141 Mil) to Dec. 2025 (€121 Mil).

Bio-Rad Laboratories Other Current Liabilities Related Terms

Bio-Rad Laboratories Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Other Current Liabilities Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 113.22 160.15 148.19 140.58 121.01

Bio-Rad Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.82 151.73 108.89 121.01 133.12
FRA:BUWA
71GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €133 Mil mean?
Bio-Rad Laboratories (FRA:BUWA) has a Other Current Liabilities of €133 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bio-Rad Laboratories.
Is Bio-Rad Laboratories' Other Current Liabilities too high?
Bio-Rad Laboratories' current Other Current Liabilities is €133 Mil. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Other Current Liabilities compare to GKOS and BRKR?
Bio-Rad Laboratories' Other Current Liabilities of €133 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bio-Rad Laboratories. Bio-Rad Laboratories's current Other Current Liabilities is €133 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €277.82, compared to a current price of €266.00 — trading 4.3% below its estimated fair value. The current Other Current Liabilities is €133 Mil. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Other Current Liabilities is €133 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €266.00 is trading 4.3% below its estimated GF Value™ of €277.82. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for FRA:BUWA:

  • Other Current Liabilities: €133 Mil
  • GF Value™: €277.82 vs. price of €266.00 (4.3% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score

Get the complete analysis for FRA:BUWA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€266.00
Price
€277.82
GF Value